AmplifAI, an AI-powered platform for contact center performance, secured $33.7 million in Series B funding and credit facility. This AmplifAI funding round was led by CVS Health Ventures. Existing investors LiveOak Ventures and Dallas Venture Partners also participated. This investment will advance AmplifAI's mission to unify human and AI agent performance.
Advancing AI for Customer Experience
AmplifAI's platform transforms enterprise contact center operations. It ensures human agents handle complex interactions. Meanwhile, AI agents seamlessly manage routine contacts. The company applies generative AI to multi-channel data. This uncovers customer pain points and generates real-time coaching.
The platform unifies customer surveys, voice recordings, and chat data. It also integrates chatbot conversations with metrics and behavioral data. This comprehensive approach drives efficiency and measurable outcomes. For instance, it has increased sales conversion by over 100%.
AmplifAI serves midmarket and Fortune 500 companies. Its clients span healthcare, financial services, and retail sectors. The company aims to reduce friction and strengthen customer loyalty. Competitors in this space include Genesys and Five9.
This AI-driven customer service solution helps organizations optimize their workforce. It also improves operational efficiency. AmplifAI funding supports its expansion into new markets. The company was recognized as a Gartner Cool Vendor in 2024.
AmplifAI's technology helps businesses achieve significant results. It reduces cost per contact by nearly 10%. Furthermore, it improves resolution rates by over 20%. This demonstrates the platform's impact on enterprise software solutions.
AmplifAI reimagines the contact center with an AI-first approach.
